Infobox Company company name Amgen Inc. company logo Image Amgen.svg company type Public company Public ... States Dollar US 14.6 Billion small FY 2009 small ref name 09IncomeStatement wikinvest stock Amgen AMGN Data Income Statement Amgen AMGN annual SEC income statement filing via Wikinvest ref operating ... wikinvest stock Amgen AMGN Data Balance Sheet Amgen AMGN annual SEC balance sheet filing via Wikinvest ... index.php?symbol AMGN&page quotesearch title Company Profile for Amgen Inc AMGN accessdate 2008 10 21 ref homepage http www.amgen.com www.amgen.com Amgen Inc. nasdaq AMGN , hkex 4332 is an international ... in the Conejo Valley , Amgen is the world s largest independent biotech firm. The company employs approximately ... biopharmaceutical products at the time of their respective releases. BusinessWeek ranked Amgen ... and development spending, combined with capital spending, to total outlays Amgen had the fourth highest ratio, at 506 1000. Amgen is the largest employer in Thousand Oaks, California Thousand Oaks and second ..., Amgen abruptly halted construction on the plans and instead put the convert 365000 sqft m2 2 of new space on the sublease market. ref cite news title Amgen Slows its Bay Area Expansion work San ..., Amgen began sponsoring the Tour of California , one of only three major Union Cycliste Internationale events in the United States . History Image AMGenelogo.jpg thumb right AMGen Corporate Logo, 1983 Image G5 N551GA 070919 04cr 16.jpg thumb right Amgen s corporate Gulfstream V departs Fox Field , Lancaster, California The word AMGen is a portmanteau of the company s original name, A pplied M olecular ... Corporation ref http www.amgen.com media media pr detail.jsp?year 2002&releaseID 515163 Amgen Completes ... media pr detail.jsp?year 2006&releaseID 837754 Amgen Completes Acquisition of Abgenix Acquisition Provides Amgen with Full Ownership of Panitumumab and Eliminates a Denosumab Royalty ref 2006 Avidia ... As of June 7, 2010, Amgen had eleven approved drug s for sixteen conditions conditions lists are highly ... more details
Unreferenced stub auto yes date December 2009 Kirin Amgen, Inc. Kirin Amgen is a biotechnology joint venture between Kirin Brewery Company, Ltd. and Amgen . It is based in Thousand Oaks, California, USA. See also Kirin Amgen v Hoechst Marion Roussel , a case decided by the House of Lords in which Kirin Amgen, Inc. was the claimant . Category Joint ventures US company stub ... more details
Kirin Amgen, Inc. v Hoechst Marion Roussel Ltd. ref cite BAILII country UK litigants Kirin Amgen, Inc ... was whether the claims of a European patent granted to Kirin Amgen, Inc. were infringed by Transkaryotic .... Infringement was not found due to the language used in the claims of the Amgen patent. The reasoning ... to the patented invention. See also Doctrine of equivalents . Background Kirin Amgen, Inc. Amgen ... DNA recombinant DNA technology . Amgen sued Shire plc Transkaryotic Therapies, Inc. TKT for patent ... and stimulates the production of red blood cells by the bone marrow . Kirin Amgen s invention versus TKT s invention The Amgen team succeeded for the first time in establishing the correct DNA ... sequence. The Amgen patent addressed introducing this newly characterised gene into another organism ... transfected microbial host cells operated to construct the desired product, EPO. The Amgen technique ... would not ordinarily express the EPO glycoprotein. The essential difference between Amgen s EPO and TKT ... a desired product was not generally known at the time that the Amgen patent application was published, and was not addressed in the Amgen patent specification or claims. Infringement The principal issue in the case was whether TKT s EPO fell outside the claims of Amgen s patent suit because of the difference in the way it was made. The key Amgen claims in issue can be summarised as 1 a DNA sequence .... Claim 26 cannot be understood without interpretation of claim 1. Amgen s claims Amgen ... , and Lord Brown of Eaton under Heywood The Amgen decision on its facts Interpreting the claims of the Amgen patent in the context of its specification, the claims are concerned with the expression ... works by a technique not generally known at the time when the Amgen patent application was published ... Amgen s appeal. The other lords all agreed. Consequences This case affirmed, without doubt, the Catnic ... 2 External links http www.uniset.ca other cs2 1915AC705.html Kirin Amgen v Hoechst full case report ... more details
Summary logo fur Article Amgen Use Org ADDITIONAL INFORMATION Used for Owner Website http www.amgen.com img misc About CompanyHistory.jpg History Commentary OVERRIDE FIELDS Description Source Portion Low resolution Purpose Must be specified if Use is not Infobox Org Brand Product Replaceability other information Amgen Inc. owns the copyright to this logo. URL http www.amgen.com img misc About CompanyHistory.jpg Licensing Non free logo ... more details
Summary Information Description Levi Leipheimer winning Stage 5 of the Amgen Tour of California. Source I created this work entirely by myself. Date 2 23 2007 Author User Gbcue Gbcue User talk Gbcue talk other versions Licensing self cc by sa 3.0 GFDL ... more details
Summary Information Description A view of the Topa Topa Mountains and Amgen from Newbury Road in Newbury Park 34.183606, 118.918355 , facing north. Source I created this work entirely by myself. Date January 7, 2008 Author Tdv294 other versions Licensing self cc by 3.0 ... more details
Richard Nanula has served as Chief Financial Officer of AmgenAmgen Inc. biotechnology since August 2001 and as Executive Vice President since May 2001. On April 10, 2007 Amgen announced that he would be resigning from his position to pursue other opportunities. He will be at Amgen until July 2007 to assist in the transition. He is being replaced by Robert Bradway. Nanula was a member of Amgen s executive committee. Additionally, on May 4, 2007, it was announced that Mr. Nanula resigned from The Boeing Company s board of directors where he had served on the board since January 2005. Mr. Nanula served as Chairman and Chief Executive Officer at Broadband Sports Broadband Sports Inc. , internet media company from 1999 until 2001. He served as President and Chief Operating Officer for Starwood Hotels and Resorts in New York from 1998 until 1999. He held a variety of executive positions at the Walt Disney Company from 1986 until 1998, including Senior Executive Vice President, Chief Financial Officer and President of Disney Stores Worldwide. He was on the Board of Director of The Boeing Company from January 2005 to May 2007. Announced in January 2008, Mr. Nanula joined Colony Capital, LLC, and is responsible for the Firm s global operations, with a special focus on operating company transactions. Sources http www.boeing.com news releases 2007 q2 070504c nr.html Boeing Director Nanula Resigns from Board http www.colonyinc.com execs nanula.htm Colony Capital Senior Excutives Richard D. Nanula US business bio stub DEFAULTSORT Nanula, Richard Category American businesspeople Category Chief financial officers Category Boeing people Category Living people ... more details
ATOC may refer to Acoustic thermometry Amgen Tour of California Association of Train Operating Companies see also Atoc , an Inca general disambig Short pages monitor This long comment was added to the page to prevent it being listed on Special Shortpages. It and the accompanying monitoring template were generated via Template Longcomment. Please do not remove the monitor template without removing the comment as well. ... more details
Infobox Person born Kevin W. Sharer image Replace this image male.svg image size caption birth date birth place death date death place occupation Chairman of the board spouse parents children Kevin W. Sharer is Chairman of the Board and Chief Executive Officer of Amgen Inc. He also serves on the Board of 3M , Northrop Grumman , and the California Institute of Technology . Bio at http www.referenceforbusiness.com biography S Z Sharer Kevin W 1948.html. Compensation While CEO of Amgen in 2008, Kevin W. Sharer earned a total compensation of 13,780,489, which included a base salary of 1,561,923, a cash bonus of 3,875,000, stocks granted of 4,253,240, and options granted of 3,559,629, as well as 530,697 in other compensation. ref http www.equilar.com CEO Compensation Amgen Kevin W. Sharer.php 2008 CEO Compensation for Kevin W. Sharer , Equilar.com ref References reflist 3M Took over CEO role from Gordon Binder http www.referenceforbusiness.com biography S Z Sharer Kevin W 1948.html Persondata Metadata see Wikipedia Persondata . NAME Sharer, Kevin W ALTERNATIVE NAMES SHORT DESCRIPTION DATE OF BIRTH 1948 PLACE OF BIRTH DATE OF DEATH PLACE OF DEATH DEFAULTSORT Sharer, Kevin W Category American chief executives Category Businesspeople in the pharmaceutical industry Category Living people Category Amgen Category 1948 births US CEO stub pt Kevin W. Sharer ... more details
Summary Information Description A view of the Topa Topa Mountains and Amgen from Newbury Road in Newbury Park 34.183606, 118.918355 , facing north. Source I created this work entirely by myself. Date January 7, 2008 Author User Tdv294 Tdv294 User talk Tdv294 talk other versions Licensing self cc by 3.0 ... more details
SureClick is a trademarked medical device, produced by Amgen and Wyeth Pharmaceuticals . The product is sold pre filled with drugs from these corporations. The device itself is a needle based, spring loaded, plunger piston drive autoinjector drug delivery device . It is disposable, self injectable, pen shaped, and portable. The SureClick autoinjector is available for both Aranesp for anemia and Enbrel for rheumatoid arthritis . A previous product, the Neulasta SureClick injector, was recalled in 2006 due to malfunctions of the injector which failed to dispense the proper dosage. ref cite news url http www.renalbusiness.com articles legal 71h1512105578058.html title European recall of Neulasta SureClick not connected to Aranesp work Renal Business Today date November 7, 2006 ref ref http www.sehd.scot.nhs.uk publications DC20061004DrugAlert.pdf Recall Notice of Neulasta SureClick . National Health Service UK Scotland. 2006 ref All three are classified as combination product by FDA as such, the two remaining on the market are regulated in the United States as drug products and not medical devices. ref cite news url http www.bio medicine.org medicine news Amgen introduces Autoinjector For Treating Anemia 13996 1 title Amgen introduces Autoinjector For Treating Anemia date September 8, 2006 publisher bio medicine.com ref Product history Autoinjectors have been in the market as long as pen injectors in the 1990s first pen introduced in 1984 for insulin but their use was restricted to emergency medical technicians . Reusable autoinjectors have been used since the 1990s for syringe based hormone replacement. In 2005 the European Union approved SureClick with Aranesp for chemotherapy ... 884743 title Amgen s Second Quarter 2006 Adjusted Earnings Per Share, Excluding Stock Option ... title Amgen Launches Aranesp Darbepoetin Alfa Prefilled SureClick Autoinjector for Treatment of Anemia ... patients products.html Amgen product list http www.amgn.com pdfs medical reimbursement aranesp sureclick ... more details
Gordon Binder is currently managing director of Coastview Capital, LLC, and previously was chairman and CEO of Amgen . ref http money.cnn.com magazines fortune fortune archive 2004 05 03 368529 CNN, May 2004 ref He joined Amgen in 1982, and previously had executive roles at the United Geophysical Corporation and the System Development Corporation . ref http query.nytimes.com gst fullpage.html?res 940DE5D61E30F934A15753C1A96E948260 New York Times, October 1988 ref Binder is chairman of SRU Biosystems . ref http www.businessweek.com technology content may2004 tc20040525 0850 tc148.htm Business Week May 2004 ref He is a member of the Board of Trustees of the American Enterprise Institute , a think tank that is one of the country s main bastions of neoconservatism . ref name People for the American Way. 2007 . Right Wing Organizations American Enterprise Insititue. cite web url http www.pfaw.org pfaw general default.aspx?oid 4456 title People for the American Way. 2007 . Right Wing Organizations American Enterprise Insititue. accessdate 2007 09 12 ref ref http www.aei.org about filter.,contentID.20038142214500073 default.asp AEI Board of Trustees ref References reflist Persondata Metadata see Wikipedia Persondata . NAME Binder, Gordon ALTERNATIVE NAMES SHORT DESCRIPTION DATE OF BIRTH PLACE OF BIRTH DATE OF DEATH PLACE OF DEATH DEFAULTSORT Binder, Gordon Category American chief executives Category Living people Business bio stub ... more details
Motesanib is the base molecule for Motesanib diphosphate AMG 706 which is an orally administered small molecule antagonist of VEGF receptor s 1,2, and 3, platelet derived growth factor receptor s and stem cell factor receptor s. ref name Monet2011 cite news url http www.genengnews.com gen news highlights amgen and takeda s nsclc drug fails in phase iii study 81244902 title Amgen and Takeda s NSCLC Drug Fails in Phase III Study date 30 Mar 2011 ref In 2011 it was reported a phase III trial did not show benefit for advanced non squamous Non small cell lung carcinoma NSCLC . ref name Monet2011 The drug is separately undergoing Phase II evaluation as first line therapy for breast cancer . ref name Monet2011 There has been a clinical trial for thyroid cancer . ref http news.cancerconnect.com motesanib diphosphate provides anticancer activity among patients with progressive thyroid cancer ref Referennces reflist External links http pubchem.ncbi.nlm.nih.gov summary summary.cgi?sid 47208329 NCBI Motesanib structure etc http www.chemblink.com products 453562 69 1.htm Motesanib molecular details Uncategorized date April 2011 pharma stub ... more details
David Goeddel born 1951 in San Diego is a pioneer of the biotechnology industry who, employed at the time by Genentech , successfully used genetic engineering to coax bacteria into creating synthetic human insulin , human growth hormone , and human TPA for use in therapeutic medicine. By contrast, the pharmaceutical industries had been researching synthetically created versions of those proteins. Recruited by Robert A. Swanson Bob Swanson in 1978, he was the first non university scientist to be hired ref name Forbes1999 cite web url http members.forbes.com asap 1999 0531 090a 2.html title Biotechnology All Stars author Eric W. Pfeiffer publisher Forbes date 1999 05 31 ref at Genentech , and the company s third employee. ref name Forbes1999 Goeddel became legendary in the biotechnology and molecular biology fields by cloning virtually all of Genentech s early products and or processes, including synthetic insulin , growth hormone , and TPA , often beating out bigger and more established laboratories in the process. Besides being perhaps the single most important contributor to Genentech s rise to one of the nation s premier biotech companies, his extraordinary drive and competitive work ethic embodied Genentech s early Clone or Die culture ref name Invisible Frontiers Invisible Frontiers The Race to Synthesize a Human Gene by Stephen S. Hall 1987, Tempus Books of Microsoft Press ref Together with Steve McKnight and Robert Tjian , he founded Tularik in 1991, and was their president and CEO until Tularik was acquired by Amgen for 1.3 billion dollars in 2004 ref cite web url http www.amgen.com media media pr detail.jsp?year 2004&releaseID 509295 title Amgen to Acquire Tularik for 1.3 Billion date 2004 03 29 author Amgen publisher Amgen ref Goeddel earned his bachelor s degree in chemistry from the University of California, San Diego , and his PhD from the University of Colorado, Boulder . He is a member of the United States National Academy of Sciences National Academy ... more details
www.jco.org cgi pmidlookup?view long&pmid 18725648 ref It was developed by the company Amgen . ref http www.amgen.com science pipe denosumab.html Denosumab from Amgen. ref Denosumab is designed to target ... amgens bone strengthening drug prolia title FDA clears Amgen s bone strengthening drug Prolia author ... induced osteoclast activity. Effectiveness Amgen has reported on two clinical trials designed and funded ... approval United States On 13 August 2009, an Amgen press release regarding the meeting that day ... ablation for prostate cancer. ref cite web title Amgen Issues Statement on Outcomes of Advisory Committee ... url http www.urotoday.com 3401 browse categories prostate cancer amgen issues statement on outcomes ... business publisher New York Times title F.D.A. Says No to an Amgen Bone Drug date 19 October 2009 last ... cite news url http www.genengnews.com gen news highlights amgen s denosumab cleared by fda for second indication 81244270 title Amgen s Denosumab Cleared by FDA for Second Indication date 19 Nov ... pr detail.jsp?year 2009&releaseID 1367560 publisher Amgen title Amgen Receives CHMP Positive Opinion ... Internationally, because of Amgen s relatively weak GP sales force, Amgen is partnering with GlaxoSmithKline ... cite news work Yahoo Finance News date December 21, 2009 title Amgen Closer to Prolia Approval author Zacks Equity Research url http finance.yahoo.com news Amgen Closer to Prolia zacks 2903308367.html ... React to FDA Panel It Wasn t a Perfect Day for Amgen url http blogs.wsj.com health 2009 08 14 analysts react to fda panel it wasnt a perfect day for amgen author Jacob Goldstein date August 14 ... date September 7, 2009 author Dimitra Defotis title At Amgen, a Prescription for Success url http online.barrons.com ... Category Monoclonal antibodies Category Amgen de Denosumab es Denosumab it Denosumab ... more details
Drugbox verifiedrevid 403990625 type mab image mab type mab source u target TRAIL R2 CD262 CAS number 896731 82 1 ATC prefix none ATC suffix synonyms anti TRAIL receptor 2 monoclonal antibody, AMG 655 PubChem DrugBank KEGG Ref keggcite correct kegg KEGG D09329 C 6466 H 10006 N 1730 O 2024 S 40 molecular weight 145.65 kDa bioavailability protein bound metabolism elimination half life excretion pregnancy AU A B1 B2 B3 C D X pregnancy US A B C D X pregnancy category legal AU S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled legal CA Schedule I, II, III, IV, V, VI, VII, VIII legal UK GSL, P, POM, CD, or Class A, B, C legal US OTC Rx only Schedule I, II, III, IV, V legal status Conatumumab originally AMG 655 is a monoclonal antibody developed for the treatment of cancer. it is a fully human monoclonal agonist antibody directed against the extracellular domain of human TRAIL tumor necrosis factor related apoptosis inducing ligand receptor 2 Tumor necrosis factor receptor TR 2, death receptor 5 with potential antineoplastic activity. Conatumumab mimics the activity of native TRAIL, binding to and activating TR 2, thereby activating caspase cascades and inducing tumor cell apoptosis . TR 2 is expressed by a variety of solid tumors and cancers of hematopoietic origin. ref http www.ama assn.org ama1 pub upload mm 365 conatumumab.pdf Statement On A Nonproprietary Name Adopted By The USAN Council Conatumumab , American Medical Association . ref ref http www.cancer.gov Templates drugdictionary.aspx?CdrID 573083 National Cancer Institute Definition of conatumomab ref The drug was developed by Amgen Inc. Clinical trials It will be included in the forthcoming I SPY2 breast cancer trial. ref http www.reuters.com article idUSN1612347120100317 Breast cancer study aims to speed drugs, cooperation March 2010 ref References references Monoclonals for tumors Category Amgen monoclonal antibody stub it Conatumumab ... more details
Peter Teeley is an United States American political consultant and diplomat, who served as press secretary to Vice President of the United States Vice President George Bush, Sr. from 1980 to 1985 and as United States Ambassador to Canada from 1992 to 1993. He was press secretary to United States Senate Senators Robert P. Griffin and Jacob Javits prior to joining Gerald Ford s campaign staff in 1976. ref http www.ford.utexas.edu LIBRARY guides Finding 20Aids PFC 20Press.htm Gerald Ford Presidential Library and Museum Press Office Records . ref Following Ford s defeat in that year s United States Presidential election, 1976 presidential election , he became communications director for the Republican National Committee , and joined Bush s campaign staff in 1980. ref Herbert S. Parmet, George Bush The Life of a Lone Star Yankee . ref He left the White House in 1985 to launch his own consulting firm, but was later appointed as the American representative to the United Nations Children s Fund in 1990. ref Teeley Goes to U.N. Fund . Washington Post , March 16, 1990. ref He was appointed Ambassador to Canada in 1992, and served until February 28, 1993, shortly after Bill Clinton succeeded Bush to the presidency. He subsequently joined Amgen as its vice president of government and public relations. ref Amgen eyes Boston area . Boston Globe , August 10, 1993. ref Teeley was diagnosed with cancer in 1991. He subsequently published a book about his treatment and recovery, The Complete Cancer Survival Guide , in 2000. ref http search.barnesandnoble.com The Complete Cancer Survival Guide Peter Teeley e 9780385486057 The Complete Cancer Survival Guide at Barnes & Noble barnesandnoble.com . ref References reflist 2 US Ambassadors to Canada DEFAULTSORT Teeley, Peter Category American political consultants Category United States ambassadors to Canada Category American health and wellness writers Category Living people US diplomat stub da Peter Teeley ... more details
with Amgen, Roche and Lundbeck involving therapeutic monoclonal antibodies with multiple indications ... 1Corporate 20Documents Genmab Uk web.ashx ref Partnerships Amgen In May of 1999, Genmab entered a sub license agreement with Amgen where it would gain rights to the IL15 antibodies. In October 2001, this was replaced by a direct license agreement where Amgen retained exclusive commercialization options for the products through phase II. Amgen has also expanded its agreement to a new antibody program targeting additional disease targets. Amgen has discontinued development of the IL15 antibody ... studies. Amgen is exploring options to maximize the value of this asset, but as this time, no further ... more details
Amgen accessdate 25 September 2009 ref Clinical uses Cinacalcet is indicated for the treatment of secondary ... 2 External links http www.sensipar.com Sensipar website run by Amgen http www.sensipar.com pdf sensipar ... more details
Gilbert Omenn , M.D., Ph.D is Professor of Internal Medicine , Human Genetics , and Public Health at the University of Michigan . He is the director of the UM Center for Computational Medicine & Biology and the Proteomics Alliance for Cancer Research. He served as Executive Vice President for Medical Affairs and as Chief Executive Officer of the University of Michigan Health System from 1997 to 2002. He was formerly Dean of the School of Public Health, and Professor of Medicine and Environmental Health, University of Washington , Seattle. He served as Associate Director, Office of Science and Technology Policy , and Associate Director, Office of Management and Budget, in the Executive Office of the President in the Carter Administration . He is a longtime director of Amgen Inc. and of Rohm & Haas Company http www.rohmhaas.com . He is a member of the Council and leader of the http www.hupo.org research hppp Plasma Proteome Project for the international Human Proteome Organization http www.hupo.org . He is Chairman of the Board 2006 2007 of the American Association for the Advancement of Science AAAS . He is also on the advisory board of NextServices http www.nextservices.net . DEFAULTSORT Omenn, Gilbert Category Living people Category Proteomics ... more details
Infobox Language name Aigon region parts of West New Britain West New Britain Province , Papua New Guinea familycolor Austronesian speakers 2000 2003 SIL fam2 Malayo Polynesian languages Malayo Polynesian fam3 Oceanic languages Oceanic fam4 Western Oceanic languages Western Oceanic fam5 North New Guinea languages North New Guinea fam6 Ngero Vitiaz languages Ngero Vitiaz fam7 Southwest New Britain languages Southwest New Britain fam8 Arawe Pasismanua languages Arawe Pasismanua fam9 Pasismanua languages Pasismanua iso3 aix Aigon is an Austronesian languages Austronesian language spoken by about 2000 individuals between the Avio and Amgen rivers in West New Britain West New Britain Province , Papua New Guinea on the island of New Britain . External links ethnologue code aix Category Western Oceanic languages Category Languages of West New Britain Province au lang stub hr Aighon jezik pms Lenga aigon ... more details
26th, 2007 the Northwest Kidney Centers based in Seattle, WA and Kirin Amgen announced an honorary ... ni article.asp?articleID 36862 UW press release NW Kidney Centers, Kirin Amgen to establish endowed ... . ref name kidney.org In 2005 Eschbach was awarded the International Society of Nephrology Amgen ... more details
drugbox IUPAC name CAS number 330988 75 5 ATC prefix none ATC suffix PubChem DrugBank KEGG D05393 C 502 H 758 N 154 O 165 S 16 molecular weight 12,103 g mol protein part bioavailability N A metabolism elimination half life excretion pregnancy category legal status investigational routes of administration subcutaneous injection Pegsunercept is a pharmaceutical drug drug for the treatment of rheumatoid arthritis . As of 2010 1 , Phase II clinical trial s have been completed. ref ClinicalTrialsGov NCT00037700 Evaluation of the Efficacy of Combination Treatment With Anakinra and Pegsunercept in Improving Rheumatoid Arthritis ref ref ClinicalTrialsGov NCT00111423 Evaluating the Safety of Extended Treatment With Pegsunercept PEG sTNF RI in Subjects With Rheumatoid Arthritis RA ref ref name Furst pmid 16331754 ref It is being developed by Amgen . Similarly to etanercept , pegsunercept is a soluble CD120 tumor necrosis factor receptor . Pegsunercept is a PEGylated protein. ref name Furst References reflist Immunosuppressants Category TNF alpha inhibitors Category Immunosuppressants antineoplastic drug stub ... more details
Dynepo is a form of pharmaceutical erythropoietin EPO under development as a pharmaceutical product by Shire Pharmaceuticals Group Shire Pharmaceuticals . The first development steps were performed by HMR and Aventis. Aventis obtained the license in Europe in 2002. The company expects to launch the product in Europe in 2006, although patents held by the United States of America American biotechnology company Amgen Amgen, Inc. may preclude its sale in the United States. EPO is a natural human hormone that stimulates formation of red blood cell s. Pharmaceutical EPO, made via recombinant DNA technology is used to treat anemia , but it has also been used by blood doping doping athletes to improve their aerobic performance and stamina. Unlike existing forms of pharmaceutical EPO manufactured in cell culture cultured animal cells , Dynepo is to be made in cultured human cells. It is therefore expected to have an authentic human form of sialic acid and other oligosaccharide residues. This characteristic may make it a longer acting product than existing brands, but clinical data have not yet been made public. It should also make Dynepo undetectable in the existing urine test for EPO used to detect doping by athletes. However, on September 28, 2007, the French sports newspaper L Equipe reported that the French anti doping laboratory LNDD had detected Dynepo in the urine of Michael Rasmussen during the 2007 Tour de France . Rasmussen was sacked by his own team while leading the Tour, because of irregularities in his reporting of his whereabouts during the lead up to the tour. The story also remarked that Dynepo was found in the urine of several other riders, yet criteria for a positive test for Dynepo are not defined. On July 1, 2009, professional cycling team ct SIL 2009 announced that Thomas Dekker cyclist Thomas Dekker was tested positive for dynepo on a test taken on December 24, 2007, while Dekker was riding for ct RAB 2007 . br br Dynepo Pharmaceutical References br ht ... more details
Encyclopedia
top
